연구성과로 돌아가기

2023 연구성과별 연구자 정보 (1322 / 2675)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Hyperviscosity Syndrome-related Retinopathy in a Patient with Waldenström Macroglobulinemia Lee, Hye Jin Lee, HJ 1 Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea kykyuri@gmail.com;
Hyperviscosity Syndrome-related Retinopathy in a Patient with Waldenström Macroglobulinemia Kim, Jin Young Kim, JY 2 Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea kykyuri@gmail.com;
Hyperviscosity Syndrome-related Retinopathy in a Patient with Waldenström Macroglobulinemia Kim, Yu Min Kim, YM 3 Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea kykyuri@gmail.com;
Hyperviscosity Syndrome-related Retinopathy in a Patient with Waldenström Macroglobulinemia Do, Jae Rock Do, JR 4 Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea kykyuri@gmail.com;
Hyperviscosity Syndrome-related Retinopathy in a Patient with Waldenström Macroglobulinemia Park, Dong Ho Park, DH 5 Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea kykyuri@gmail.com;
Hyperviscosity Syndrome-related Retinopathy in a Patient with Waldenström Macroglobulinemia Shin, Jae Pil Shin, JP 6 Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea kykyuri@gmail.com;
Hyperviscosity Syndrome-related Retinopathy in a Patient with Waldenström Macroglobulinemia Kang, Yong Koo Kang, YK 7 교신저자 Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea IVH-8723-2023 KANG, YONG KOO 0000-0002-6505-315X Kang, Yong Koo kykyuri@gmail.com;
Hyperviscosity Syndrome-related Retinopathy in a Patient with Waldenström Macroglobulinemia Kang, Yong Koo Kang, YK 7 교신저자 Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, 130 Dongdeok Ro, Daegu 41944, South Korea IVH-8723-2023 KANG, YONG KOO 0000-0002-6505-315X Kang, Yong Koo kykyuri@gmail.com;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Miklos, David Bernard Miklos, DB 1 교신저자 Stanford Univ, Sch Med, Stanford, CA 94305 USA 0000-0003-0717-4305 Miklos, David dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Abu Zaid, Mohammad Abu Zaid, M 2 Indiana Univ, Melvin & Bren Simon Canc Ctr IUSCC, Indianapolis, IN USA AFO-3625-2022 Abu Zaid, Mohammad 0000-0002-4018-6941 Abu Zaid, Mohammad dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Cooney, Julian P. Cooney, JP 3 Fiona Stanley Hosp, Murdoch, Australia dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Cooney, Julian P. Cooney, JP 3 Univ Western Australia, Crawley, Australia dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Albring, Joern C. Albring, JC 4 Univ Munster, Munster, Germany 0000-0002-5534-7250 Albring, Jorn dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Flowers, Mary Flowers, M 5 Fred Hutchinson Canc Res Ctr, Seattle, WA USA 0000-0003-1631-0911 Flowers, Mary dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Skarbnik, Alan P. Skarbnik, AP 6 John Theurer Canc Ctr, Hackensack, NJ USA dmiklos@stanford.edu;
페이지 이동: